Symptoms and Epidemiology of Iron Deficiency Anemia

Panelists discuss how iron deficiency anemia manifests through debilitating symptoms, including severe fatigue, weakness, shortness of breath, headaches, and difficulty concentrating, which can profoundly impact patients’ daily functioning, work performance, and overall quality of life.

EP: 1.Background and Causes of Iron Deficiency Anemia

EP: 2.Pathophysiology of Iron Deficiency Anemia

Now Viewing

EP: 3.Symptoms and Epidemiology of Iron Deficiency Anemia

Video content above is prompted by the following:

• What are the symptoms of IDA symptoms, and how do they impact patients’ quality of life?

Related Videos

Related Content

Advertisement

January 9th 2025

Nomogram Predicts Overall Survival in Patients With Ovarian Cancer, Liver Metastases

Brooke McCormick

Researchers developed and validated a nomogram to predict 1-, 2-, and 3-year overall survival (OS) in patients with ovarian cancer and liver metastases (OCLM), outperforming an external model in stability and accuracy.

December 23rd 2024

Five Years Later: Ongoing COVID-19 Challenges, Next Steps

Brooke McCormick

On this episode of Managed Care Cast, we speak with Jenny Han, MD, of Emory School of Medicine and Grady Hospital, about COVID-19, long COVID, and strategies for prevention and care.

January 9th 2025

Real-World Discontinuations of Ocrelizumab in MS Comparable to Pivotal Trials

AJMC Contributor

Data from a systematic review of 30 real-world studies show comparable discontinuation rates of ocrelizumab to those in pivotal clinical trials among patients with different types of multiple sclerosis (MS).

December 17th 2024

Diving Into Patient Preferences for Blood Cancer Treatments With Dr Sikander Ailawadhi

Three abstracts presented at the 2024 American Society of Hematology annual meeting focused on patient preferences and treatment choices in blood cancers.

January 8th 2025

Ruxolitinib Combinations in MPNs: Updates From ASH

Mary Caffrey

For several years, investigators have been studying combinations that include ruxolitinib, sold as Jakafi, to treat myeloproliferative neoplasms (MPNs).

January 8th 2025

AI-Powered Clinical Alerts Show Promise in Suicide Risk Prevention

Giuliana Grossi

Doctors conducted suicide risk assessments for 42% of patients flagged by interruptive alerts, compared with only 4% with passive alerts.

Related Content

Advertisement

January 9th 2025

Nomogram Predicts Overall Survival in Patients With Ovarian Cancer, Liver Metastases

Brooke McCormick

Researchers developed and validated a nomogram to predict 1-, 2-, and 3-year overall survival (OS) in patients with ovarian cancer and liver metastases (OCLM), outperforming an external model in stability and accuracy.

December 23rd 2024

Five Years Later: Ongoing COVID-19 Challenges, Next Steps

Brooke McCormick

On this episode of Managed Care Cast, we speak with Jenny Han, MD, of Emory School of Medicine and Grady Hospital, about COVID-19, long COVID, and strategies for prevention and care.

January 9th 2025

Real-World Discontinuations of Ocrelizumab in MS Comparable to Pivotal Trials

AJMC Contributor

Data from a systematic review of 30 real-world studies show comparable discontinuation rates of ocrelizumab to those in pivotal clinical trials among patients with different types of multiple sclerosis (MS).

December 17th 2024

Diving Into Patient Preferences for Blood Cancer Treatments With Dr Sikander Ailawadhi

Three abstracts presented at the 2024 American Society of Hematology annual meeting focused on patient preferences and treatment choices in blood cancers.

January 8th 2025

Ruxolitinib Combinations in MPNs: Updates From ASH

Mary Caffrey

For several years, investigators have been studying combinations that include ruxolitinib, sold as Jakafi, to treat myeloproliferative neoplasms (MPNs).

January 8th 2025

AI-Powered Clinical Alerts Show Promise in Suicide Risk Prevention

Giuliana Grossi

Doctors conducted suicide risk assessments for 42% of patients flagged by interruptive alerts, compared with only 4% with passive alerts.